UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000028164
Receipt number R000032238
Scientific Title A study on objective findings and subjective symptoms in asthenopia after VDT work
Date of disclosure of the study information 2017/07/11
Last modified on 2018/01/09 10:15:27

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study on objective findings and subjective symptoms in asthenopia after VDT work

Acronym

A study on asthenopia after VDT work

Scientific Title

A study on objective findings and subjective symptoms in asthenopia after VDT work

Scientific Title:Acronym

A study on asthenopia after VDT work

Region

Japan


Condition

Condition

Healthy adult

Classification by specialty

Ophthalmology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To examine the relationship between subjective symptoms and objective findings of asthenopia after VDT work

Basic objectives2

Others

Basic objectives -Others

Correlation between the differences of the accommodative microfluctuation (HFC67cm) value and the VAS value in the morning and the evening

Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Correlation between the differences of the accommodative microfluctuation (HFC67cm) value and the VAS value in the morning and the evening

Key secondary outcomes

1. Correlation between the differences of the value of HFC1
, HFC2 and the average of HFC value and the VAS value in the morning and the evening
2. Changes of HFC 1, HFC 67 cm, HFC 2, the average of HFC value (HFC parameters) in the morning and evening
3. Presence or absence of background factors affecting changes of HFC parameters in the morning and evening


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification

YES

Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Device,equipment

Interventions/Control_1

Measurement of accomdative microfluctuation value by ARK 560 A

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Healty adult and person who agreed to participate in this research

Key exclusion criteria

1. A person with myopia exceeding -6 D
2. A person with hyperopia
3. A person who is taking measures against presbyopia (use of reading glasses or bifocal glasses, always removing eyeglasses for VDT work, etc)
4. People who have undergone surgery of LASIK
5. Person who is aware of intense astigmatism
6. Person who is inserting multifocal intraocular lens

Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Toshihide Suenobu

Organization

Senju Pharmaceutical Co., Ltd

Division name

Medical Science Department, Research & Development Division

Zip code


Address

2-5-8 Hiranomachi, Chuo-ku, Osaka Japan

TEL

06-6201-2552

Email

t-suenobu@senju.co.jp


Public contact

Name of contact person

1st name
Middle name
Last name Futoshi Miyamoto

Organization

Senju Pharmaceutical Co., Ltd.

Division name

Clinical Resarch Management Group,

Zip code


Address

2-5-8 Hiranomachi, Chuo-ku, Osaka Japan

TEL

06-6201-2552

Homepage URL


Email

f-miyamoto@senju.co.jp


Sponsor or person

Institute

Senju Pharmaceutical Co., Ltd.
Clinical Resarch Management Group,

Institute

Department

Personal name



Funding Source

Organization

Senju Pharmaceutical Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

千寿製薬株式会社


Other administrative information

Date of disclosure of the study information

2017 Year 07 Month 11 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2017 Year 07 Month 10 Day

Date of IRB


Anticipated trial start date

2017 Year 07 Month 24 Day

Last follow-up date

2017 Year 10 Month 06 Day

Date of closure to data entry

2017 Year 10 Month 06 Day

Date trial data considered complete

2017 Year 11 Month 09 Day

Date analysis concluded

2018 Year 03 Month 31 Day


Other

Other related information



Management information

Registered date

2017 Year 07 Month 10 Day

Last modified on

2018 Year 01 Month 09 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032238


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name